A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine
In this retrospective study, Nirmatrelvir/Ritonavir and Simnotrelvir/Ritonavir exerts stronger potency on reducing duration of hospital stays in hospitalized patient with COVID-19, suggestive of a better choice for antiviral therapy. Patients who fail to take antiviral drugs in time after symptom onset would still benefit from these antiviral regimens. Additional well-designed clinical trials with large sample size are still needed to further confirm the effectiveness of these antivirals.
Authors
- Guijuan Xie
- Xiyue Li (ORCID: https://orcid.org/0000-0001-7331-8544)
- Ximiao Yu (ORCID: https://orcid.org/0009-0001-6809-693X)
- Jiehong Wang
- Ruiqi Luo (ORCID: https://orcid.org/0009-0001-8405-2515)
- Xiaojun Qian (ORCID: https://orcid.org/0000-0003-2547-7107)
- Xun Wang (ORCID: https://orcid.org/0000-0003-0916-3634)
- Jiali Ji (ORCID: https://orcid.org/0000-0003-3252-0054)
Institutions
- Jiangnan University (CN)
- Nantong University (CN)
- The First People's Hospital of Changzhou (CN)
- Wuxi No.2 People's Hospital (CN)
- Wuxi People's Hospital (CN)
- Pulmonary and Critical Care Associates (US)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/idr.s477083
- Citations
- 2
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- China Postdoctoral Science Foundation